BioNTech, the vaccine maker collaborating with Pfizer, is set to seek worldwide approval for its COVID-19 vaccine for children between the ages of 5 and 11 within the coming weeks, according to company executives.
“Already over the next few weeks, we will file the results of our trial in five to 11-year olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe,” Chief Medical Officer Oezlem Tuereci told Der Spiegel, according to Reuters.
Read More